title: Venlafaxine-induced depression of wind-up activity in mononeuropathic rats is potentiated by inhibition of brain 5-HT1A receptor expression in vivo.
abstract: Antinociceptive effects of inhibiting 5-HT1A receptor expression by intracerebroventricular administration of an antisense oligodeoxynucleotide were studied in mononeuropathic rats. A 7-day period of treatment with the antisense produced: (i) reduction of mechanical hyperalgesia in the neuropathic hindlimb starting from day 5 of treatment, (ii) decrease of the hypothermic effect of 8-OH-DPAT challenge on day 6 of treatment, and (iii) potentiation of the inhibitory effect of velafaxine on spinal wind-up activity on day 7 of treatment. Results suggest a counteracting role of somatodendritic 5-HT1A receptors of raphe nuclei neurons in the antinociceptive efficacy of antidepressants with serotonergic spectrum in neuropathic pain.
authors.affiliation: Faculty of Chemistry and Biology, University of Santiago of Chile, Santiago, Chile. ahernand@lauca.usach.ed
authors.forename: Alejandro
authors.initials: A
authors.lastname: Hernández
authors.forename: Luis
authors.initials: L
authors.lastname: Constandil
authors.forename: Claudio
authors.initials: C
authors.lastname: Laurido
authors.forename: Teresa
authors.initials: T
authors.lastname: Pelissier
authors.forename: Fabien
authors.initials: F
authors.lastname: Marchand
authors.forename: Denis
authors.initials: D
authors.lastname: Ardid
authors.forename: Abdelkrim
authors.initials: A
authors.lastname: Alloui
authors.forename: Alain
authors.initials: A
authors.lastname: Eschalier
authors.forename: Rubén
authors.initials: R
authors.lastname: Soto-Moyano
mesh_terms: D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal; D001831:Body Temperature / Q000187:drug effects; D003511:Cyclohexanols; D003863:Depression / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005334:Fever / Q000139:chemically induced / Q000188:drug therapy; D006930:Hyperalgesia / Q000188:drug therapy* / Q000209:etiology; D015918:Infusion Pumps, Implantable; D008297:Male; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D010147:Pain Measurement / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D044282:Receptor, Serotonin, 5-HT1A / Q000235:genetics; D012018:Reflex / Q000187:drug effects; D012043:Regression, Psychology; D020426:Sciatic Neuropathy / Q000139:chemically induced / Q000188:drug therapy*; D058829:Serotonin 5-HT1 Receptor Antagonists; D017367:Selective Serotonin Reuptake Inhibitors; D013997:Time Factors; D000069470:Venlafaxine Hydrochloride
chemical_list: D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D003511:Cyclohexanols; D016376:Oligonucleotides, Antisense; D044282:Receptor, Serotonin, 5-HT1A; D058829:Serotonin 5-HT1 Receptor Antagonists; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride